Recent News & Events
-
2020
-
2019
-
2018
-
2017
-
2016
<
>
(click on bold, green text for links)
|
December
29 |
Olatec Therapeutics’ Lead Compound, Dapansutrile, a Selective NLRP3 Inhibitor, Prevents the Inflammatory Response and Restores Cognitive and Behavioral Deficits in a Mouse Model of Alzheimer’s Disease
NEW YORK--(BUSINESS WIRE) -- Olatec Therapeutics LLC (“Olatec”) today announced the publication of data demonstrating the benefits of its selective NLRP3 inhibitor, dapansutrile, in a mouse model of Alzheimer’s Disease (AD). The data are published in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS). The study shows oral dosing with dapansutrile inhibits pathophysiological inflammatory processes, recovers significant cognitive losses and prevents neuroinflammation in the brains of transgenic mice induced with Alzheimer’s Disease (AD)…Continue Reading |
|
October
27 |
Olatec Enrolls its First Patients in a Phase 2 Placebo-Controlled Clinical Trial in COVID-19 with its Selective NLRP3 Inhibitor, Oral Dapansutrile
(New York, NY — October 27, 2020) Olatec Therapeutics LLC announced today that it is currently enrolling non-hospitalized COVID-19 patients with the aim to treat and prevent damaging effects of IL-1-induced inflammation that can lead to a fulminant Cytokine Storm. The trial is described as: “A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome.” … Continue Reading |
|
June
29 |
One of the world’s premier societies of cardiology, the European Society of Cardiology (ESC), accepted the abstract, “Safety of a novel oral NLRP3 inflammasome inhibitor, dapansutrile (OLT1177), in patients with stable heart failure with reduced ejection fraction” as a virtual poster at ESC’s 2020 Congress.
Olatec's poster presents the positive results of our Phase 1b Heart Failure Study, in which Dr. Antonio Abbate, leading cardiologist at Virginia Commonwealth University, was the Principal Investigator on the study. In his assessment of the study outcome, Dr. Abbate states, “We are all enthusiastic about the continued development of dapansutrile in cardiovascular disease and its clean safety profile. Dapansutrile's findings provide preliminary safety evidence and data for NLRP3 inhibition in patients who are expected to poorly tolerate side effects of NSAIDs or glucocorticoids." About ESC: ESC represents more than 95,000 professionals in the field of cardiology, focused on understanding the impact of cardiovascular disease and how we can better reduce its burden. |
|
June
23 |
A Frontiers in Immunology publication, entitled "Targeting the NLRP3 Inflammasome in Severe COVID-19”, underscores the validation of the NLRP3 target in treating cytokine release syndrome in COVID-19. Table 1 of the publication cites Olatec’s lead compound, dapansutrile, as the most advanced selective NLRP3 inhibitor in Phase 2 clinical trials in a broad spectrum of diseases.
|
|
June
19 |
Olatec’s CSO & SAB chair, Charles Dinarello MD announced as a joint winner of the 2020 Tang Prize in Biopharmaceutical Science for his groundbreaking achievements establishing IL-1β as a potent mediator of fever and inflammatory diseases.
“[Dinarello laid the groundwork for] the development of biopharmaceuticals that have benefited millions of people suffering from autoimmune and inflammatory diseases”, said the Tang Prize Foundation said today. The Tang Prize Foundation, established in 2012, awards its biannual prize across four categories, including scientists that aim to find a 21st century path to the sustainable development of the world. Link to article's here and here, and watch a video of Dr. Dinarello’s acceptance of the 2020 Tang Prize, where Charles documents his monumental discovery of IL-1β, a potent mediator of fever and inflammatory diseases. |
|
May
11 |
Reuters Health published, in Medscape, “Dapansutrile Appears Safe, Effective in Gout Patients”. The article quotes Dr. Michael H. Pillinger of NYU School of Medicine/NYU Langone Medical Center, “Now, thanks to a decade of advances in inflammation science, we understand the central role of the NLRP3 inflammasome, and of IL-1β in particular, in the pathogenesis of gout…This understanding has allowed the development of dapansutrile, which is likely destined to become the first agent designed specifically to treat gouty inflammation...”
|
|
Apr
23 |
Olatec’s NLRP3 inhibitor, dapansutrile, is cited in "Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease” in the Circulation Research, in which the publication stated, “There is overwhelming evidence linking the NLRP3 inflammasome and the IL-1 cytokines with the pathogenesis of CVDs."
|
|
Apr
8 |
Olatec’s CSO, Charles Dinarello MD, discusses dapansutrile, an oral NLRP3 inhibitor, as an optimal target to prevent and treated the inflammatory cytokine storm in COVID-19 patients, during a grand rounds featured presentation for Colorado University’s Department of Medicine.
See also CU News Release. |
|
Apr
7 |
We are pleased to report that The Lancet Rheumatology published our paper, "Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial" along with a third-party commentary entitled, "Dapansutrile: a new hope?". Olatec's publication presents the successful results of our clinical proof of concept trial for dapansutrile in acute gout. Acute gout was strategically selected as it is a prototypical NLRP3 mediated disease, validating the potential for our NLRP3 inhibitor in a broad spectrum of inflammatory diseases.
|
|
Feb
17 |
Olatec cited in the C&EN cover story entitled “Could an NLRP3 inhibitor be the one drug to conquer common diseases?”
|
|
Nov
11-12 |
At the world’s leading organization for rheumatology health professionals - Olatec presented its datasets demonstrating significant clinical antiinflammatory effect and clean safety profile with oral dapansutrile in the treatment of acute gout attacks in oral and poster presentations. The acceptance of these two abstracts by American College of Rheumatology (ACR) and Association of Rheumatology Professionals (ARP) for presentations at their 2019 Annual Meeting in Atlanta, Georgia provides further validation of the positive results in our first human Phase 2 trial of an oral NLRP3 inflammasome inhibitor. About ACR/ARP: since its beginnings over 80 years ago, today, ACR draws more than 16,000 attendees from more than 100 countries to its Annual Meeting each year. (In compliance with ACR’s disclaimer requirements, this news release is being made solely by Olatec).
|
|
Nov
1 |
Olatec’s fourth peer-reviewed publication and first publication on the benefits of dapansutrile in preclinical models of neurodegenerative disease, specifically in multiple sclerosis (MS), published in Frontiers Immunology. In this publication, “OLT1177 (dapansutrile), a selective NLRP3 inhibitor, ameliorates experimental autoimmune encephalomyelitis pathogenesis,” we show that oral treatment of dapansutrile – an NLRP3 inhibitor – delays and reduces disease progression in a mouse model of MS. These data provide justification of the potential clinical benefit of dapansutrile in MS patients. Frontiers Immunology ranks as the 5th most-cited publisher among the 20 largest publishers in 2019.
Link to publication, here. |
|
Oct
14 |
Charles Dinarello MD, co-CSO and Chairman of Olatec’s Scientific Advisory Board, presents “Treating Inflammation with IL-1 Blockade from Gout to Cancer”, in which he presents data on dapansutrile, at ITMAT’s 14th Annual International Symposium – Translational Targets and Precision Medicine: Taming Inflammation and Improving Resilience as We Age in Philadelphia, PA.
|
|
Oct
1 |
Carlo Marchetti, PhD, Director for Olatec’s Innovative Science Program in Dr. Charles Dinarello’s Laboratory, publishes a review entitled “The NLRP3 inflammasome as pharmacological target”, in the Journal of Cardiovascular Pharmacology, in which Olatec’s lead compound, dapansutrile, is referenced
Read More |
|
Oct
1 |
A review of Olatec’s lead compound, dapansutrile (lab code: OLT1177®), appears in the Journal of Cardiovascular Pharmacology publication entitled “Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes”co-authored by Leo F. Buckley, PharmD and Olatec Scientific Advisory Board Member, Peter Libby, MD.
Read More |
|
Sep
28 |
Olatec’s lead compound, dapansutrile, referenced in Arthritis & Research publication entitled, "The Clinicopathologic Significance of Inflammasome Activation in Autoimmune Diseases"
Read More |
|
Sep
12 |
Olatec’s lead compound (OLT1177® dapansutrile) referenced in Nature Reviews Rheumatology publication by Charles Dinarello MD, CSO and Chairman of Olatec’s Scientific Advisory Board entitled, "The IL-1 family of cytokines and receptors in rheumatic diseases". The publication represents a further validation for dapansutrile in its acute gout flares and osteoarthritis clinical indications.
Read More |
|
Sep
9 |
The Company established Olatec Therapeutics BV, a wholly-owned subsidiary in the Netherlands (“Olatec BV”).
|
|
Sep
1 |
Olatec’s lead compound, dapansutrile, referenced in Journal of Cardiovascular Pharmacology publication entitled, "Drugs to Inhibit the NLRP3 Inflammasome: Not Always On Target"
Read More |
|
Sep
1 |
Olatec’s lead compound, dapansutrile, referenced in Journal of Cardiovascular Pharmacology publication entitled, "Cardiovascular Pharmacology of the NLRP3 Inflammasome"
Read More |
|
Sep
1 |
Olatec’s lead compound, dapansutrile, referenced in Journal of Cardiovascular Pharmacology publication entitled, "NLRP3 Inflammasome in Acute Myocardial Infarction"
Read More |
|
Aug
28 |
Olatec Therapeutics announces that dapansutrile met its primary and secondary endpoints in a Phase 2a trial (Study OLT1177-05) of patients with acute gout flares. This trial represents the first known selective NLRP3 inhibitor to demonstrate clinical benefit, safety and a reduction in systemic inflammation. Datasets on the clinical, inflammatory biomarker and safety outcomes will be presented this November at a prestigious conference.
|
|
Jun
13 |
Olatec’s lead compound, dapansutrile, referenced in Gout 1st Edition book entitled, "Gout: Chapter 17 Drugs in the Pipeline”, authored by Naomi Schlesinger, MD
Read More |
|
Jun
10 |
Olatec’s lead compound, dapansutrile, referenced in the Journal of Allergy and Clinical Immunology publication entitled, "A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: Therapeutic efficacy of proton pump inhibitors”
Read More |
|
Jun
4 |
Olatec’s lead compound, dapansutrile, referenced in Nature Reviews Nephrophology publication entitled, " The role of inflammasomes in kidney disease”
Read More |
|
Apr
29 |
Olatec’s lead compound, dapansutrile, referenced in Nature Reviews Immunology publication entitled, ”The NLRP3 inflammasome: molecular activation and regulation to therapeutics"
Read More |
|
Apr
23 |
Olatec’s lead compound, dapansutrile, referenced in EMBO Molecular Medicine publication entitled, ”Inflammasomes in neuroinflammatory and neurodegenerative diseases"
Read More |
|
Mar
31 |
Charles Dinarello MD, CSO and Chairman of Olatec’s Scientific Advisory Board presents select data on dapansutrile at the 10th Biannual Meeting of the International Society of Systemic Auto-Inflammatory Diseases (ISSAID) in Genoa, Italy.
|
|
Mar
21 |
Olatec’s lead compound, dapansutrile, referenced in The Journal of Organic Chemistry publication entitled, "Discovery of Quinazolin-4(3H)-ones as NLRP3 Inflammasome Inhibitors: Computational Design, Metal-free Synthesis and In-vitro Biological Evaluation”
Read More |
|
Mar
4 |
Olatec’s lead compound, dapansutrile, referenced in Kidney International publication entitled, “Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases”
Read More |
|
Feb
12 |
Olatec’s lead compound, dapansutrile, referenced in Nature Cell Death & Disease publication entitled, “Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors”
Read More |
|
Feb
10 |
Timotheus L.Th.A. Jansen, MD PhD joins and becomes Chairman of the Olatec Clinical Advisory Board. Mr. Jansen has been contributing leading expertise in the design and conduct of Olatec’s human clinical trials in gout including serving as the principal investigator of the first clinical trial with dapansutrile for acute gout flares.
See Bio |
|
Feb
8 |
Olatec manuscript published in Journal of Cardiovascular Pharmacology entitled, "The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse”
Read More |
|
December
21 |
Olatec’s lead compound, dapansutrile, referenced in Cardiovascular Research publication entitled, “Innate immunity as a target for acute cardioprotection”
Read More |
|
December
4 |
Olatec’s lead compound, dapansutrile, referenced in Frontiers in Neurology publication entitled, “Rusty Microglia: Trainers of Innate Immunity in Alzheimer's Disease”
Read More |
|
November
21 |
Bob Fielding joins the Olatec Scientific Advisory Board. Mr. Fielding is contributing leading expertise in the design and conduct of Olatec’s pharmacology programs. Mr. Fielding has over 30 years experience in the pharmaceutical and biotech industries, including with formulation evaluation, preclinical pharmacokinetics/toxicokinetics, pharmacology and clinical pharmacokinetic studies for more than 30 products now approved or in clinical trials.
See Bio |
|
November
21 |
Steve Newhard joins the Olatec Scientific Advisory Board. Mr. Newhard has over 40 years of experience in the pharmaceutical and regulatory industry and is responsible for manufacturing of Olatec's Lead Compound at CMOs producing the active drug substance and drug product.
See Bio |
|
September
5-7 |
Charles Dinarello MD, CSO and Chairman of Olatec’s Scientific Advisory Board, and Leo Joosten PhD, Olatec SAB Member, presents select data on dapansutrile at the New Frontiers in Innate Immunity & Inflammation in Cluj Napoca, Romania.
|
|
August
31 |
Olatec referenced in American Journal of Physiology-Heart and Circulatory Physiology publication entitled, “Inflammasome, Pyroptosis, and Cytokines in Myocardial Ischemia-Reperfusion Injury”
Read More |
|
August
14 |
Olatec’s lead compound, dapansutrile, referenced in Psychoneuroendocrinology publication entitled, “Emerging role of the P2X7-NLRP3-IL1β pathway in mood disorders”
Read More |
|
August
3 |
Olatec manuscript published in Arthritis Research & Therapy entitled, "NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis”
Read More |
|
July
20 |
Olatec’s lead compound, dapansutrile, referenced in Nature Reviews Drug Discovery publication entitled, "Targeting the NLRP3 inflammasome in inflammatory diseases”
Read More |
|
April
4 |
Olatec referenced in Nature Scientific Reports publication entitled,"Development of a characterised tool kit for the interrogation of NLRP3 inflammasome-dependent responses”
Read More |
|
March
1 |
Charles Dinarello MD, CSO and Chairman of Olatec’s Scientific Advisory Board, presents select data on dapansutrile at the European Crystal Network Workshop in Paris, France.
|
|
February
23 |
Olatec referenced in European Heart Journal, published on behalf of European Society of Cardiology, entitled, "Interleukin-1 blockade in cardiovascular diseases: a clinical update”
Read More |
|
January
29 |
Olatec’s research manuscript published in Proceedings of the National Academy of Sciences, entitled "OLT1177, a β‑sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation”.
Read More |
|
June
14 |
Carlo Marchetti, PhD, Director for Olatec’s Innovative Science Program in Dr. Charles Dinarello’s Laboratory, presents, “The Human Safe NLRP3 Inflammasome Inhibitor OLT1177 Suppresses Joint Inflammation in Murine Models of Experimental Arthritis” at EULAR conference in Madrid, Spain
|
|
April
21 |
Carlo Marchetti, PhD, Director for Olatec’s Innovative Science Program in Dr. Charles Dinarello’s Laboratory, presents poster, “The Novel and Safe Pharmaceutical Compound OLT1177 Reduces Inflammation by Preventing Activation of the NLRP3 inflammasome” at AAP/ASCI/APSA Meeting in Chicago, IL
|
|
March
19 |
Antonio Abbate, MD, PhD joins the Olatec Scientific Advisory Board. Dr. Abbate is a prominent leader in the field of cardiovascular disease
|
|
November
16 |
Olatec referenced in Nature Reviews Cardiology entitled, "The NLRP3 inflammasome in acute myocardial infarction”
|
|
November
12 |
Stefano Toldo, PhD, Virginia Commonwealth University Assistant Professor, Department of Internal Medicine Division of Cardiology, presents poster, “Novel NLRP3 Inflammasome Inhibitor OLT1177 Reduces Infarct Size in a Mouse Model of Myocardial Ischemia Reperfusion Injury” at the AHA conference in Anaheim, CA
|
|
October
11 |
Olatec referenced in Nature Biotechnology entitled, “Novartis trial validates inflammasome as chronic disease driver”
|
|
November
27 |
Franz Hefti, PhD joins the Olatec Scientific Advisory Board. Dr. Hefti is a prominent leader in the development of neurodegenerative therapeutics and an experienced biotech CEO
|